Agnete Overgaard Donskov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Agnete Overgaard Donskov has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Kresten Krarup Keller
Department of Rheumatology Aarhus University Hospital Aarhus Denmark
6 shared publications - Ellen-Margrethe Hauge
Department of Rheumatology Aarhus University Hospital Aarhus Denmark
5 shared publications - Andreas Wiggers Nielsen
Department of Rheumatology, Aarhus University Hospital , Aarhus
3 shared publications - Annette de Thurah
Department of Rheumatology Aarhus University Hospital Aarhus Denmark
2 shared publications - Berit Dalsgaard Nielsen
Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Rheumatology, Horsens Regional Hospital, Horsens, Denmark
2 shared publications - Christoffer Søvsø Våben
Department of Rheumatology, Aarhus University Hospital , Aarhus
2 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by Wiley in Arthritis & Rheumatology
Incidence and Disease Course of Polymyalgia Rheumatica During Two Decades: A Nationwide Study Across Health Care Sectors in Denmark
Objective: A new algorithm enables the identification of patients with polymyalgia rheumatica (PMR) across health care sectors in Denmark. We estimated annual incidence rates from 2003 to 2024 and described the disease course, including the occurrence of late‐onset giant cell arteritis (GCA) and prednisolone or prednisone (PDN) treatment. Methods: A Danish nationwide, population‐based cohort study was conducted using data linked at the individual level. Cases were identified among people ages 50 years or older between January 1, 2003, and November 1, 2024. Results: A total of 51,401 patients were identified, including 24,456 from primary care and 26,945 from secondary care. The age‐standardized incidence of PMR was 112 per 100,000 people (95% confidence interval [CI] 110.8–112.8). During the study period, the incidence declined by 53% in primary health care and increased by 30% in secondary health care, resulting in an overall decline of 12%. Among patients with PMR, GCA occurred at a rate of 5.4 (95% CI 5.1–5.7) per 1,000 patient‐years, with a median of 68 days (interquartile range 10–602) from PMR diagnosis. Overall, 28% and 22% of patients were still treated with PDN after 5 and 10 years, with a median daily dose of 4.1 and 5.5 mg of PDN, respectively. Conclusion: The increasing incidence of PMR in secondary health care was exceeded by the declining incidence in primary health care. Most late‐onset GCA developed within the first year after PMR diagnosis. Many patients continued treatment with PDN for 5 to 10 years, indicating a need for earlier use of concomitant therapies.
- 23 September 2026
- Published by Wiley in Arthritis & Rheumatology
Open AccessIncidence and Disease Course of Polymyalgia Rheumatica During Two Decades: A Nationwide Study Across Health Care Sectors in Denmark
Objective: A new algorithm enables the identification of patients with polymyalgia rheumatica (PMR) across health care sectors in Denmark. We estimated annual incidence rates from 2003 to 2024 and described the disease course, including the occurrence of late‐onset giant cell arteritis (GCA) and prednisolone or prednisone (PDN) treatment. Methods: A Danish nationwide, population‐based cohort study was conducted using data linked at the individual level. Cases were identified among people ages 50 years or older between January 1, 2003, and November 1, 2024. Results: A total of 51,401 patients were identified, including 24,456 from primary care and 26,945 from secondary care. The age‐standardized incidence of PMR was 112 per 100,000 people (95% confidence interval [CI] 110.8–112.8). During the study period, the incidence declined by 53% in primary health care and increased by 30% in secondary health care, resulting in an overall decline of 12%. Among patients with PMR, GCA occurred at a rate of 5.4 (95% CI 5.1–5.7) per 1,000 patient‐years, with a median of 68 days (interquartile range 10–602) from PMR diagnosis. Overall, 28% and 22% of patients were still treated with PDN after 5 and 10 years, with a median daily dose of 4.1 and 5.5 mg of PDN, respectively. Conclusion: The increasing incidence of PMR in secondary health care was exceeded by the declining incidence in primary health care. Most late‐onset GCA developed within the first year after PMR diagnosis. Many patients continued treatment with PDN for 5 to 10 years, indicating a need for earlier use of concomitant therapies.
- 21 March 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (4)
Rheumatologist assessment in established polymyalgia rheumatica
Objectives: Patients with established polymyalgia rheumatica (PMR) are often referred from general practitioners (GPs) to rheumatologists. This single-centre cohort study examined the frequency, indications and diagnostic outcomes of patients with established PMR referred to a rheumatology outpatient clinic after initial diagnosis by GPs or rheumatologists in a hospital outpatient setting. Methods: This single-centre retrospective cohort study included patients with established PMR referred to a department of rheumatology (2018–2024). Data from patient records covered time of referral, PMR diagnosis, discharge, re-referral, and indication for and outcome of rheumatologist assessment of patients with established PMR. Symptoms and clinical findings were also documented. Results: Among 237 patients diagnosed by rheumatologists, 52/204 (26%) of discharged patients were re-referred. They had shorter time from diagnosis to discharge than those not re-referred (median: 41 days vs 230 days, P < 0.01). Referrals of the 98 patients diagnosed by GPs were more often prompted by uncertainty about their primary diagnosis of PMR (51% vs 14%, P < 0.01), and less frequently by relapse (27% vs 50%, P < 0.01) or recurrence (11% vs 31%, P < 0.01) compared with patients diagnosed by rheumatologists. The PMR diagnosis was less frequently maintained in patients diagnosed by GPs compared with patients diagnosed by rheumatologists (62% vs 83%, P < 0.05). Conclusion: Re-referral was common among patients with established PMR, and the risk increased with discharge shortly after PMR diagnosis. The diagnosis was revised in one-third of patients diagnosed by GPs, highlighting diagnostic challenges and supporting referral of individuals suspected of PMR consistent with current recommendations.
- 21 March 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (4)
Rheumatologist assessment in established polymyalgia rheumatica
Objectives: Patients with established polymyalgia rheumatica (PMR) are often referred from general practitioners (GPs) to rheumatologists. This single-centre cohort study examined the frequency, indications and diagnostic outcomes of patients with established PMR referred to a rheumatology outpatient clinic after initial diagnosis by GPs or rheumatologists in a hospital outpatient setting. Methods: This single-centre retrospective cohort study included patients with established PMR referred to a department of rheumatology (2018–2024). Data from patient records covered time of referral, PMR diagnosis, discharge, re-referral, and indication for and outcome of rheumatologist assessment of patients with established PMR. Symptoms and clinical findings were also documented. Results: Among 237 patients diagnosed by rheumatologists, 52/204 (26%) of discharged patients were re-referred. They had shorter time from diagnosis to discharge than those not re-referred (median: 41 days vs 230 days, P < 0.01). Referrals of the 98 patients diagnosed by GPs were more often prompted by uncertainty about their primary diagnosis of PMR (51% vs 14%, P < 0.01), and less frequently by relapse (27% vs 50%, P < 0.01) or recurrence (11% vs 31%, P < 0.01) compared with patients diagnosed by rheumatologists. The PMR diagnosis was less frequently maintained in patients diagnosed by GPs compared with patients diagnosed by rheumatologists (62% vs 83%, P < 0.05). Conclusion: Re-referral was common among patients with established PMR, and the risk increased with discharge shortly after PMR diagnosis. The diagnosis was revised in one-third of patients diagnosed by GPs, highlighting diagnostic challenges and supporting referral of individuals suspected of PMR consistent with current recommendations.
- 20 November 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Repeated short corticotropin testing in patients with polymyalgia rheumatica
Objective: To investigate adrenal function and the prevalence of glucocorticoid (GC) induced adrenal insufficiency (GIAI) in patients with polymyalgia rheumatica (PMR), the first 18 months after diagnosis. Methods: Newly diagnosed patients with PMR underwent short corticotropin tests before commencement of GC treatment and after 10 weeks, 6 months, and 12 months. Patients still on GC or with GIAI after 12 months were invited to a test after 18 months. GIAI was defined as a stimulated serum cortisol level <420 nmol/l. Results: : Sixty patients with PMR were enrolled. The mean (S.D.) stimulated cortisol levels declined significantly between baseline (678 ± 95) and month 6 (491 ± 114), followed by an increase at month 12 (549 ± 100). An inverse relationship was found between stimulated cortisol levels and current GC dose (P < 0.001). The proportion of GIAI peaked at month 6 (13/53, 25%) when all patients received GC. By 12 months, adrenal function had recovered in 12/13 (92%) of these patients. At month 12 and month 18, GIAI was present in 1/31 (3%) and 0/12 (0%), who were no longer receiving GC. Conclusion: Stimulated serum cortisol levels in patients with PMR did not reach pretreatment levels after cessation of GC treatment. GIAI was frequent but reversible during GC treatment for PMR, which supports the concept of increased GC dosing during stress in these patients. Implementation of routine use of the short corticotropin test for the diagnosis of GIAI after planned cessation of GC treatment in PMR is not justified by our data. Trial registration: Clinicaltrials.gov, http://clinicaltrials.gov, NCT04519580.
- 20 November 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Repeated short corticotropin testing in patients with polymyalgia rheumatica
Objective: To investigate adrenal function and the prevalence of glucocorticoid (GC) induced adrenal insufficiency (GIAI) in patients with polymyalgia rheumatica (PMR), the first 18 months after diagnosis. Methods: Newly diagnosed patients with PMR underwent short corticotropin tests before commencement of GC treatment and after 10 weeks, 6 months, and 12 months. Patients still on GC or with GIAI after 12 months were invited to a test after 18 months. GIAI was defined as a stimulated serum cortisol level <420 nmol/l. Results: : Sixty patients with PMR were enrolled. The mean (S.D.) stimulated cortisol levels declined significantly between baseline (678 ± 95) and month 6 (491 ± 114), followed by an increase at month 12 (549 ± 100). An inverse relationship was found between stimulated cortisol levels and current GC dose (P < 0.001). The proportion of GIAI peaked at month 6 (13/53, 25%) when all patients received GC. By 12 months, adrenal function had recovered in 12/13 (92%) of these patients. At month 12 and month 18, GIAI was present in 1/31 (3%) and 0/12 (0%), who were no longer receiving GC. Conclusion: Stimulated serum cortisol levels in patients with PMR did not reach pretreatment levels after cessation of GC treatment. GIAI was frequent but reversible during GC treatment for PMR, which supports the concept of increased GC dosing during stress in these patients. Implementation of routine use of the short corticotropin test for the diagnosis of GIAI after planned cessation of GC treatment in PMR is not justified by our data. Trial registration: Clinicaltrials.gov, http://clinicaltrials.gov, NCT04519580.
- 19 November 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (5) , 3210-3211
Comment on: ‘Real-world outcomes of a dedicated fast-track polymyalgia rheumatica clinic’
- 19 November 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (5) , 3210-3211
Comment on: ‘Real-world outcomes of a dedicated fast-track polymyalgia rheumatica clinic’
- Open Access
- 24 May 2024
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 137 (15-16) , 463-469
Socioeconomic equality in initiation of biologic treatment in Danish patients with inflammatory bowel disease
Summary: Background: Low socioeconomic status is associated with disadvantages in health outcomes and delivery of medical care in patients with Inflammatory Bowel Disease (IBD). Inequality in the utilisation of biologic treatment is largely unexplored. Aim: To explore the potential association of socioeconomic status and time to first biologic treatment in a population-based IBD cohort. Methods: All 37,380 IBD incidences between 2000 and 2017 from the Danish National Patient Register were identified and linked to socioeconomic information including educational level, income and occupational status at diagnosis. Hazard ratios for receiving biologic treatment among socioeconomic groups were estimated using Cox proportional hazard regression. Results: No difference in time between diagnosis and biologic treatment initiation was found comparing patients with upper secondary, vocational, or academic education to those with lower secondary education in patients with IBD. Patients with Crohn’s disease in the two highest income quartiles received biologic treatment earlier (HR 1.16; 95% CI: 1.04; 1.30 & HR 1.15; 95% CI: 1.03; 1.30). An elevated treatment rate was found for persons with “other” occupational status (unspecified source of income) compared to employed persons in patients with ulcerative colitis (HR 1.36; 95% CI: 1.11; 1.66), but not in patients with Crohn’s disease. Conclusion: This study revealed equal initiation of biologic treatment among patients with IBD across different educational background, income and occupational status. However, results are limited to a setting with free universal healthcare coverage and treatment needs should be considered and addressed in future research.
- 24 May 2024
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 137 (15-16) , 463-469
Open AccessSocioeconomic equality in initiation of biologic treatment in Danish patients with inflammatory bowel disease
Summary: Background: Low socioeconomic status is associated with disadvantages in health outcomes and delivery of medical care in patients with Inflammatory Bowel Disease (IBD). Inequality in the utilisation of biologic treatment is largely unexplored. Aim: To explore the potential association of socioeconomic status and time to first biologic treatment in a population-based IBD cohort. Methods: All 37,380 IBD incidences between 2000 and 2017 from the Danish National Patient Register were identified and linked to socioeconomic information including educational level, income and occupational status at diagnosis. Hazard ratios for receiving biologic treatment among socioeconomic groups were estimated using Cox proportional hazard regression. Results: No difference in time between diagnosis and biologic treatment initiation was found comparing patients with upper secondary, vocational, or academic education to those with lower secondary education in patients with IBD. Patients with Crohn’s disease in the two highest income quartiles received biologic treatment earlier (HR 1.16; 95% CI: 1.04; 1.30 & HR 1.15; 95% CI: 1.03; 1.30). An elevated treatment rate was found for persons with “other” occupational status (unspecified source of income) compared to employed persons in patients with ulcerative colitis (HR 1.36; 95% CI: 1.11; 1.66), but not in patients with Crohn’s disease. Conclusion: This study revealed equal initiation of biologic treatment among patients with IBD across different educational background, income and occupational status. However, results are limited to a setting with free universal healthcare coverage and treatment needs should be considered and addressed in future research.
- 13 January 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 62 (8) , 2797-2805
An international survey of current management practices for polymyalgia rheumatica by general practitioners and rheumatologists
Objectives: To explore current management practices for PMR by general practitioners (GPs) and rheumatologists including implications for clinical trial recruitment. Methods: An English language questionnaire was constructed by a working group of rheumatologists and GPs from six countries. The questionnaire focused on: 1: Respondent characteristics; 2: Referral practices; 3: Treatment with glucocorticoids; 4: Diagnostics; 5: Comorbidities; and 6: Barriers to research. The questionnaire was distributed to rheumatologists and GPs worldwide via members of the International PMR/Giant Cell Arteritis Study Group. Results: In total, 394 GPs and 937 rheumatologists responded to the survey. GPs referred a median of 25% of their suspected PMR patients for diagnosis and 50% of these were returned to their GP for management. In general, 39% of rheumatologists evaluated patients with suspected PMR >2 weeks after referral, and a median of 50% of patients had started prednisolone before rheumatologist evaluation. Direct comparison of initial treatment showed that the percentage prescribing >25 mg prednisolone daily for patients was 30% for GPs and 12% for rheumatologists. Diagnostic imaging was rarely used. More than half (56%) of rheumatologists experienced difficulties recruiting people with PMR to clinical trials. Conclusion: This large international survey indicates that a large proportion of people with PMR are not referred for diagnosis, and that the proportion of treatment-naive patients declined with increasing time from referral to assessment. Strategies are needed to change referral and management of people with PMR, to improve clinical practice and facilitate recruitment to clinical trials.
- 13 January 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 62 (8) , 2797-2805
An international survey of current management practices for polymyalgia rheumatica by general practitioners and rheumatologists
Objectives: To explore current management practices for PMR by general practitioners (GPs) and rheumatologists including implications for clinical trial recruitment. Methods: An English language questionnaire was constructed by a working group of rheumatologists and GPs from six countries. The questionnaire focused on: 1: Respondent characteristics; 2: Referral practices; 3: Treatment with glucocorticoids; 4: Diagnostics; 5: Comorbidities; and 6: Barriers to research. The questionnaire was distributed to rheumatologists and GPs worldwide via members of the International PMR/Giant Cell Arteritis Study Group. Results: In total, 394 GPs and 937 rheumatologists responded to the survey. GPs referred a median of 25% of their suspected PMR patients for diagnosis and 50% of these were returned to their GP for management. In general, 39% of rheumatologists evaluated patients with suspected PMR >2 weeks after referral, and a median of 50% of patients had started prednisolone before rheumatologist evaluation. Direct comparison of initial treatment showed that the percentage prescribing >25 mg prednisolone daily for patients was 30% for GPs and 12% for rheumatologists. Diagnostic imaging was rarely used. More than half (56%) of rheumatologists experienced difficulties recruiting people with PMR to clinical trials. Conclusion: This large international survey indicates that a large proportion of people with PMR are not referred for diagnosis, and that the proportion of treatment-naive patients declined with increasing time from referral to assessment. Strategies are needed to change referral and management of people with PMR, to improve clinical practice and facilitate recruitment to clinical trials.
- Open Access
Oral function in patients with myasthenia gravis
Myasthenia Gravis (MG) is characterised by muscle weakness and increased fatigability. The aim of this pilot study was to investigate if patients with MG demonstrate different functional chewing patterns and report more complaints related to mastication as compared with healthy controls. Twelve patients (median 60 years Q1–Q3: 46–70) with generalised MG and nine healthy controls (median 57 years Q1–Q3: 55–63) participated. All participants underwent dental and oral examination and were asked to fill in a questionnaire concerning oral health. Static maximum bite force was measured with a bite force transducer, electromyography in the masseter, temporalis, and suprahyoid muscles were recorded, and jaw movement was tracked, during a 5-minute gum chewing test. The patients had more oral complaints (oral health impact profile total score 22.6 vs 7.5 P < 0.01) and had lower peak bite force than controls (18.8kgf (11.1;26.4) (95% CI) vs 29.5 kgf (21.6; 37.4) (P = 0.04)). In contrast, fatigability of the masticatory muscles, as defined by number of chewing cycles during the gum-chewing test, did not differ between patients and controls (P = 0.10). In conclusion, patients had more oral complaints and lower bite force than controls, but did not show significantly different functional chewing patterns. Future studies should aim at integrating measurement of peak force into functional tests. Attention should be given to oral complaints of patients with MG.
Open AccessOral function in patients with myasthenia gravis
Myasthenia Gravis (MG) is characterised by muscle weakness and increased fatigability. The aim of this pilot study was to investigate if patients with MG demonstrate different functional chewing patterns and report more complaints related to mastication as compared with healthy controls. Twelve patients (median 60 years Q1–Q3: 46–70) with generalised MG and nine healthy controls (median 57 years Q1–Q3: 55–63) participated. All participants underwent dental and oral examination and were asked to fill in a questionnaire concerning oral health. Static maximum bite force was measured with a bite force transducer, electromyography in the masseter, temporalis, and suprahyoid muscles were recorded, and jaw movement was tracked, during a 5-minute gum chewing test. The patients had more oral complaints (oral health impact profile total score 22.6 vs 7.5 P < 0.01) and had lower peak bite force than controls (18.8kgf (11.1;26.4) (95% CI) vs 29.5 kgf (21.6; 37.4) (P = 0.04)). In contrast, fatigability of the masticatory muscles, as defined by number of chewing cycles during the gum-chewing test, did not differ between patients and controls (P = 0.10). In conclusion, patients had more oral complaints and lower bite force than controls, but did not show significantly different functional chewing patterns. Future studies should aim at integrating measurement of peak force into functional tests. Attention should be given to oral complaints of patients with MG.
- 27 March 2021
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 144 (1) , 76-80
Overactive bladder in patients with myasthenia gravis—A cross‐sectional population‐based study
Background In myasthenia gravis (MG), first‐line treatment for MG is acetylcholinesterase inhibitors which alleviates symptoms, but concomitantly may cause autonomic adverse effects. Aims of the study In this study, we evaluated if symptoms of overactive bladder (OAB) are more frequent among MG patients than healthy controls. Methods Eighty‐three MG patients and 50 healthy sex‐ and age‐matched controls were included and answered the questionnaire “International Consultation on Incontinence Questionnaire Overactive Bladder Module” (ICIQ‐OAB), including questions about polyuria, nocturia, urgency, and stress incontinence. Clinical severity of MG was determined based on three standardized clinical evaluations. Results Compared to control subjects, MG patients had a higher total OAB score (median 5 [range 0–12] versus 3 [0; 7]) (p < 0.005) with higher scores concerning all four items. Also, MG patients had a higher bother score (10 [0–40] versus 5 [0–40]) (p < 0.05). Patients receiving a daily dose of pyridostigmine of more than 300 mg had a higher OAB score than other patients. Conclusions Myasthenia gravis patients have more bothering symptoms of OAB than healthy controls, related to the daily dose of pyridostigmine. To minimize adverse effects in patients with symptoms of OAB, the pyridostigmine dose should be as low as possible.
- 27 March 2021
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 144 (1) , 76-80
Overactive bladder in patients with myasthenia gravis—A cross‐sectional population‐based study
Background In myasthenia gravis (MG), first‐line treatment for MG is acetylcholinesterase inhibitors which alleviates symptoms, but concomitantly may cause autonomic adverse effects. Aims of the study In this study, we evaluated if symptoms of overactive bladder (OAB) are more frequent among MG patients than healthy controls. Methods Eighty‐three MG patients and 50 healthy sex‐ and age‐matched controls were included and answered the questionnaire “International Consultation on Incontinence Questionnaire Overactive Bladder Module” (ICIQ‐OAB), including questions about polyuria, nocturia, urgency, and stress incontinence. Clinical severity of MG was determined based on three standardized clinical evaluations. Results Compared to control subjects, MG patients had a higher total OAB score (median 5 [range 0–12] versus 3 [0; 7]) (p < 0.005) with higher scores concerning all four items. Also, MG patients had a higher bother score (10 [0–40] versus 5 [0–40]) (p < 0.05). Patients receiving a daily dose of pyridostigmine of more than 300 mg had a higher OAB score than other patients. Conclusions Myasthenia gravis patients have more bothering symptoms of OAB than healthy controls, related to the daily dose of pyridostigmine. To minimize adverse effects in patients with symptoms of OAB, the pyridostigmine dose should be as low as possible.